Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C48H38F8N8O8S4 |
| Molecular Weight | 1135.111 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNS(=O)(=O)C1=CC=C(F)C(=C1F)C2=C3CCC(=N3)C(=C4NC(C=C4)=C(C5=NC(CC5)=C(C6=CC=C2N6)C7=C(F)C(=CC=C7F)S(=O)(=O)NC)C8=C(F)C(=CC=C8F)S(=O)(=O)NC)C9=C(F)C(=CC=C9F)S(=O)(=O)NC
InChI
InChIKey=CKRVBMUJCFKRND-ZXWMLXKTSA-N
InChI=1S/C48H38F8N8O8S4/c1-57-73(65,66)33-17-5-21(49)37(45(33)53)41-25-9-11-27(61-25)42(38-22(50)6-18-34(46(38)54)74(67,68)58-2)29-13-15-31(63-29)44(40-24(52)8-20-36(48(40)56)76(71,72)60-4)32-16-14-30(64-32)43(28-12-10-26(41)62-28)39-23(51)7-19-35(47(39)55)75(69,70)59-3/h5-9,11,14,16-20,57-61,64H,10,12-13,15H2,1-4H3/b41-25+,41-26+,42-27+,42-29+,43-28+,43-30+,44-31+,44-32+
| Molecular Formula | C48H38F8N8O8S4 |
| Molecular Weight | 1135.111 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
F2BMET (redaporfin or LUZ11), a fluorinated sulfonamide bacteriochlorin, is photosensitizer, with antineoplastic activity upon photodynamic therapy. F2BMET is a third generation bacteriochlorin molecule which has a greater ability to absorb light and convert it into active molecular species (reactive oxygen species), better depth penetration, and improved efficacy. F2BMET has promising Phase I/IIA POC clinical data in advanced head and neck cancer which clearly reinforces the favorable results from non-clinical studies. It has received Orphan Drug Designation (ODD) from EMA in Europe for Biliary tract cancer.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:25:01 GMT 2025
by
admin
on
Tue Apr 01 16:25:01 GMT 2025
|
| Record UNII |
ZP3QP1H44W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/15/1470
Created by
admin on Tue Apr 01 16:25:01 GMT 2025 , Edited by admin on Tue Apr 01 16:25:01 GMT 2025
|
||
|
FDA ORPHAN DRUG |
556616
Created by
admin on Tue Apr 01 16:25:01 GMT 2025 , Edited by admin on Tue Apr 01 16:25:01 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ZP3QP1H44W
Created by
admin on Tue Apr 01 16:25:01 GMT 2025 , Edited by admin on Tue Apr 01 16:25:01 GMT 2025
|
PRIMARY | |||
|
100000183241
Created by
admin on Tue Apr 01 16:25:01 GMT 2025 , Edited by admin on Tue Apr 01 16:25:01 GMT 2025
|
PRIMARY | |||
|
10170
Created by
admin on Tue Apr 01 16:25:01 GMT 2025 , Edited by admin on Tue Apr 01 16:25:01 GMT 2025
|
PRIMARY | |||
|
86287614
Created by
admin on Tue Apr 01 16:25:01 GMT 2025 , Edited by admin on Tue Apr 01 16:25:01 GMT 2025
|
PRIMARY | |||
|
1224104-08-8
Created by
admin on Tue Apr 01 16:25:01 GMT 2025 , Edited by admin on Tue Apr 01 16:25:01 GMT 2025
|
PRIMARY | |||
|
C114382
Created by
admin on Tue Apr 01 16:25:01 GMT 2025 , Edited by admin on Tue Apr 01 16:25:01 GMT 2025
|
PRIMARY | |||
|
SUB197619
Created by
admin on Tue Apr 01 16:25:01 GMT 2025 , Edited by admin on Tue Apr 01 16:25:01 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Bluepharma, Universidade de Coimbra; Developer: Luzitin; Class: Antineoplastic, Macrocyclic compound, Porphyrin; Mechanism of Action: Photosensitiser; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Available For Licensing: Yes; Highest Development Phase: Phase II for Head and neck cancer; Most Recent Events: 15 Mar 2016 Phase-II clinical trials in Head and neck cancer in Portugal (IV), 20 Feb 2014 Phase-I/II clinical trials in Head and neck cancer in Portugal (IV), 08 Dec 2012 Luzitin licensed patents by Bluepharma and Universidade de Coimbra
|